Reserpine

Reserpine (Serpalan) is an indole alkaloid antipsychotic and antihypertensive drug that irreversibly blocks the vesicular monoamine transporter (VMAT) . (In Vitro) :Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2) . Reserpine displays a significant effect on the density of dopamine D1 receptors (F2,12=8.81, p<0.01) in the rat striatum. The affinity (Kd) for the dopamine D1 and D2 receptors during withdrawal from acute and chronic administration of reserpine is not change. IC50 values of 43.9 and 54.9 μM are obtained after 1 day of treatment with Reserpine in JB6 P+ and HepG2-C8 cells, respectively. Reserpine induces luciferase activity in a dose-dependent manner at concentrations ranging from 5 to 50 μM, and no significant induction is observed at concentrations lower than 5 μM. Results demonstrate that Reserpine (2.5 to 10 μM) also increases the protein expression of Nrf2, HO-1, and NQO1. Reserpine at concentrations of 2.5 to 10 μM decreases the mRNA expression of DNMT1, DNMT3a, and DNMT3b in a concentration-dependent manner in JB6 P+ cells after 7 days of treatment. Reserpine at 10 μM generates a significant difference for DNMT3a expression (p<0.05) .

50-55-5

NSC 59272 | NSC 237659 | Rausedil

Pharmacology & Drug Discovery

>98% (HPLC)

DMSO: 13 mg/mL (21.35 mM)

CO[C@H]1[C@@H] (C[C@@H]2CN3CCC4=C ([C@H]3C[C@@H]2[C@@H]1C (=O) OC) NC5=C4C=CC (=C5) OC) OC (=O) C6=CC (=C (C (=C6) OC) OC) OC

C33H40N2O9

608.68

Storage temperature: -20°C. Stability: ≥ 2 years